On June 16, 2025, Marker Therapeutics, Inc. entered into an agreement with Cellipont Bioservices for the manufacturing of its MT-601 therapy, supporting the upcoming APOLLO study. The agreement includes technology transfer and manufacturing services over the next nine months.